Gritstone bio (GRTS) Stock Price, News & Analysis

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $0.63
• 52-Week Range: N/A
• Volume: 61.02 million shs
• Average Volume: 7.01 million shs
• Market Capitalization: $3.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.17
• Consensus Rating: Moderate Buy

Gritstone bio Stock Analysis - MarketRank™

Gritstone bio scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Gritstone bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Gritstone bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gritstone bio are expected to grow in the coming year, from ($0.79) to ($0.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gritstone bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gritstone bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GRTS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gritstone bio does not currently pay a dividend.

Dividend Growth

Gritstone bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GRTS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Gritstone bio this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for GRTS on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

2 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gritstone bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.61% of the stock of Gritstone bio is held by insiders.

Percentage Held by Institutions

48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GRTS Stock Analysis - Frequently Asked Questions

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.12. The company had revenue of $0.92 million for the quarter, compared to the consensus estimate of $2.77 million. Gritstone bio had a negative net margin of 910.50% and a negative trailing twelve-month return on equity of 328.51%.

When did Gritstone bio IPO?

Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Who are Gritstone bio's major shareholders?

Gritstone bio's top institutional investors include FMR LLC (0.40%). Insiders that own company stock include Andrew R Allen, Erin Jones, Matthew Hawryluk and Vassiliki Economides.
View institutional ownership trends.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRTS
• CUSIP: N/A
• CIK: 1656634
• Web: www.gritstoneoncology.com
• Phone: (510) 871-6100
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.17
• High Stock Price Target: $5.00
• Low Stock Price Target: $0.50
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-138,490,000.00
• Net Margins: -910.50%
• Pretax Margin: -910.50%
• Return on Equity: -328.51%
• Return on Assets: -82.53%

Debt

• Debt-to-Equity Ratio: 1.83
• Current Ratio: 2.54
• Quick Ratio: 2.54

Sales & Book Value

• Annual Sales: $496,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 108,569,000
• Free Float: 111,837,000
• Market Cap: $3.50 million
• Optionable: Optionable
• Beta: 0.49